Replication-competent herpes simplex virus mediates destruction of neoplastic cells
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 17, 1996
Grant Date -
N/A
app pub date -
Jun 23, 1994
filing date -
Jun 23, 1994
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the .sub..gamma. 34.5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully